Dryness

Dryness is not a specific molecular target, receptor, or enzyme, but rather a clinical manifestation or physiological state characterized by insufficient moisture or lubrication in tissues such as the eyes, mouth, or skin (StatPearls, 2023). It is commonly associated with underlying conditions like Sjögren's syndrome—an autoimmune disorder where the body attacks its own moisture-secreting glands—or as a side effect of pharmacological interventions such as anticholinergics and antihistamines (NIH, 2023). In the context of drug development, dryness (particularly dry eye and xerostomia) serves as an indication for therapeutic intervention rather than the target itself. Pharmacological strategies to manage dryness involve targeting specific proteins that regulate fluid secretion or inflammation. For example, muscarinic acetylcholine receptor agonists like pilocarpine are used to stimulate salivary and lacrimal glands, while anti-inflammatory agents like cyclosporine (Restasis) or lifitegrast (Xiidra) are targeted at lymphocyte-associated antigens or calcineurin to reduce the underlying inflammation in dry eye syndrome (AAO, 2023). Because 'Dryness' lacks a specific amino acid sequence or biochemical structure, it is categorized as an incorrect entry for a molecular target database and should be mapped to the specific receptors (e.g., CHRM3) or inflammatory pathways involved in its pathology.

Other names

XerosisXerostomiaSicca syndromeDesiccationKeratoconjunctivitis siccaOcular surface disease

Not applicable as a molecular target; dryness is a clinical condition or symptom treated by agonists of secretagogue receptors (e.g., M3 muscarinic receptors) or anti-inflammatory agents.